       Document 0235
 DOCN  M9440235
 TI    Neutralizing antibody responses to autologous and heterologous isolates
       of human immunodeficiency virus.
 DT    9404
 AU    Wrin T; Crawford L; Sawyer L; Weber P; Sheppard HW; Hanson CV; Viral and
       Rickettsial Disease Laboratory, California Department; of Health
       Services, Berkeley 94704.
 SO    J Acquir Immune Defic Syndr. 1994 Mar;7(3):211-9. Unique Identifier :
       AIDSLINE MED/94149554
 AB    Although laboratory-adapted strains of human immunodeficiency virus
       (HIV) are generally highly sensitive to neutralization by HIV-positive
       patient sera, we have found a more complex pattern of
       cross-neutralization and neutralization resistance among low-passage
       clinical isolates. These HIV isolates, like many other lentiviruses,
       resisted neutralization by the patient's own (autologous) antibodies. We
       assessed the degree of antigenic relatedness between different patient
       isolates of HIV through cross-neutralization with heterologous sera and
       virus isolates. Complicated patterns emerged, with variation in breadth
       of neutralization among individual plasmas and variation in frequency of
       neutralization among isolates. In longitudinal studies of individuals,
       we found that some but not all such patients develop a neutralizing
       response that catches up with their earlier isolates after a lag period.
       Taken together, these data suggest that an individual's immune response
       broadens with time because of cumulative exposure to multiple antigenic
       variants that arise throughout HIV disease.
 DE    Cells, Cultured  Cross Reactions  Human  HIV/*IMMUNOLOGY/ISOLATION &
       PURIF  HIV Antibodies/*BIOSYNTHESIS  HIV Infections/BLOOD/*IMMUNOLOGY
       Immune Sera/IMMUNOLOGY  Leukocytes, Mononuclear/MICROBIOLOGY
       Longitudinal Studies  Male  Neutralization Tests  Support, U.S. Gov't,
       P.H.S.  Time Factors  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

